166 related articles for article (PubMed ID: 11302475)
41. Fibrinolysis-adjusted perioperative low-dose aprotinin reduces blood loss in bypass operations.
Misfeld M; Dubbert S; Eleftheriadis S; Siemens HJ; Wagner T; Sievers HH
Ann Thorac Surg; 1998 Sep; 66(3):792-9. PubMed ID: 9768932
[TBL] [Abstract][Full Text] [Related]
42. Plasmin generation and fibrin(ogen)olysis following desmopressin infusion.
Takahashi H; Tatewaki W; Wada K; Niwano H; Hanano M; Shibata A
Am J Hematol; 1991 Apr; 36(4):255-8. PubMed ID: 1826408
[TBL] [Abstract][Full Text] [Related]
43. Platelets and soluble fibrin promote plasminogen activation causing downregulation of platelet glycoprotein Ib/IX complexes: protection by aprotinin.
de Haan J; van Oeveren W
Thromb Res; 1998 Nov; 92(4):171-9. PubMed ID: 9840026
[TBL] [Abstract][Full Text] [Related]
44. Postoperative hemostasis and fibrinolysis in patients undergoing cardiopulmonary bypass with or without aprotinin therapy.
Lu H; Du Buit C; Soria J; Touchot B; Chollet B; Commin PL; Conseiller C; Echter E; Soria C
Thromb Haemost; 1994 Sep; 72(3):438-43. PubMed ID: 7531877
[TBL] [Abstract][Full Text] [Related]
45. Continuous small-dose tranexamic acid reduces fibrinolysis but not transfusion requirements during orthotopic liver transplantation.
Kaspar M; Ramsay MA; Nguyen AT; Cogswell M; Hurst G; Ramsay KJ
Anesth Analg; 1997 Aug; 85(2):281-5. PubMed ID: 9249100
[TBL] [Abstract][Full Text] [Related]
46. Acute promyelocytic leukaemia and acquired alpha-2-plasmin inhibitor deficiency: a retrospective look at the use of epsilon-aminocaproic acid (Amicar) in 30 patients.
Wassenaar T; Black J; Kahl B; Schwartz B; Longo W; Mosher D; Williams E
Hematol Oncol; 2008 Dec; 26(4):241-6. PubMed ID: 18613223
[TBL] [Abstract][Full Text] [Related]
47. The ratio of concentrations of aminocaproic acid and tranexamic acid that prevent plasmin activation of platelets does not provide equivalent inhibition of plasmatic fibrinolysis.
Nielsen VG; Ford PM
J Thromb Thrombolysis; 2018 Oct; 46(3):365-370. PubMed ID: 29926296
[TBL] [Abstract][Full Text] [Related]
48. Compaction of fibrin clots reveals the antifibrinolytic effect of factor XIII.
Rijken DC; Abdul S; Malfliet JJ; Leebeek FW; Uitte de Willige S
J Thromb Haemost; 2016 Jul; 14(7):1453-61. PubMed ID: 27148673
[TBL] [Abstract][Full Text] [Related]
49. Comparison of epsilon aminocaproic acid and tranexamic Acid in thoracic aortic surgery: clinical efficacy and safety.
Makhija N; Sarupria A; Kumar Choudhary S; Das S; Lakshmy R; Kiran U
J Cardiothorac Vasc Anesth; 2013 Dec; 27(6):1201-7. PubMed ID: 24050855
[TBL] [Abstract][Full Text] [Related]
50. Aprotinin and epsilon aminocaproic acid are effective in reducing blood loss after primary total hip arthroplasty--a prospective randomized double-blind placebo-controlled study.
Ray M; Hatcher S; Whitehouse SL; Crawford S; Crawford R
J Thromb Haemost; 2005 Jul; 3(7):1421-7. PubMed ID: 15978098
[TBL] [Abstract][Full Text] [Related]
51. Fluorogenic fibrinogen and fibrin facilitate macromolecular assembly and dynamic assay of picomolar levels of plasminogen activators under well mixed conditions.
Wu JH; Diamond SL
Thromb Haemost; 1995 Aug; 74(2):711-7. PubMed ID: 8585011
[TBL] [Abstract][Full Text] [Related]
52. The use of low-dose aprotinin, epsilon-aminocaproic acid or tranexamic acid for prevention of mediastinal bleeding in patients receiving aspirin before coronary artery bypass operations.
Landymore RW; Murphy JT; Lummis H; Carter C
Eur J Cardiothorac Surg; 1997 Apr; 11(4):798-800. PubMed ID: 9151061
[TBL] [Abstract][Full Text] [Related]
53. Intra- and postoperative fibrinolysis in patients undergoing cardiopulmonary bypass surgery.
Páramo JA; Rifón J; Llorens R; Casares J; Paloma MJ; Rocha E
Haemostasis; 1991; 21(1):58-64. PubMed ID: 1907591
[TBL] [Abstract][Full Text] [Related]
54. The antifibrinolytic effects of carbon monoxide-releasing molecule-2 are fibrin and alpha2-antiplasmin dependent.
Nielsen VG
Blood Coagul Fibrinolysis; 2010 Sep; 21(6):584-7. PubMed ID: 20683324
[TBL] [Abstract][Full Text] [Related]
55. Aprotinin versus tranexamic acid: the controversy continues.
Levy JH
Transfusion; 2006 Mar; 46(3):319-20. PubMed ID: 16533270
[No Abstract] [Full Text] [Related]
56. Effects of high-dose aprotinin on blood loss, platelet function, fibrinolysis, complement, and renal function after cardiopulmonary bypass.
Blauhut B; Gross C; Necek S; Doran JE; Späth P; Lundsgaard-Hansen P
J Thorac Cardiovasc Surg; 1991 Jun; 101(6):958-67. PubMed ID: 1710008
[TBL] [Abstract][Full Text] [Related]
57. Effect of antiproteolytic drugs: epsilon-aminocaproic acid (EACA) and aprotinin on experimental anti-GBM nephritis.
Hruby Z; Wendycz D; Kopeć W; Czerchawski L; Józefowiak M; Rabczyński J
Nephrol Dial Transplant; 1996 Jan; 11(1):32-9. PubMed ID: 8649650
[TBL] [Abstract][Full Text] [Related]
58. Age-based difference in activation markers of coagulation and fibrinolysis in extracorporeal membrane oxygenation.
Hundalani SG; Nguyen KT; Soundar E; Kostousov V; Bomgaars L; Moise A; Hui SK; Teruya J
Pediatr Crit Care Med; 2014 Jun; 15(5):e198-205. PubMed ID: 24614609
[TBL] [Abstract][Full Text] [Related]
59. The effective concentration of epsilon-aminocaproic Acid for inhibition of fibrinolysis in neonatal plasma in vitro.
Yurka HG; Wissler RN; Zanghi CN; Liu X; Tu X; Eaton MP;
Anesth Analg; 2010 Jul; 111(1):180-4. PubMed ID: 20519417
[TBL] [Abstract][Full Text] [Related]
60. Antifibrinolytic therapy in cardiac surgery.
Chen RH; Frazier OH; Cooley DA
Tex Heart Inst J; 1995; 22(3):211-5. PubMed ID: 7580358
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
